Previous studies have shown elevated plasma levels of IP10 during HCV infection [6,8,41,42], and pre-PEG IFN therapy, low baseline IP10 is associated with low baseline viral load, a good response to therapy, and less fibrosis, inflammation, and steatosis [42]. The gene discussed is IFNA1; the disease is steatosis.